术中腹腔内5-氟尿嘧啶缓释化疗对进展期胃癌的疗效

目的 观察术中植入5-氟尿嘧啶缓释剂对进展期胃癌术后腹腔内局部复发及患者生存率的影响.方法 回顾性分析2002年1月至2004年12月诊治100例进展期胃癌患者的临床资料,根据术中是否植入5-氟尿嘧啶缓释剂分为治疗组和对照组.治疗组于胃癌D2根治术后腹腔内植入5-氟尿嘧啶缓释剂800 mg;对照组术中未植入5-氟尿嘧啶缓释剂,两组患者术后按FOLFOX方案化疗.结果 治疗组及对照组患者术后3年生存率分别为45%和32%;3年无瘤生存率分别为28%和16%.治疗组的3年生存率和3年无瘤生存率均高于对照组.结论 术中腹腔内植入5-氟尿嘧啶缓释化疗可以降低进展期胃癌根治术后肿瘤局部复发并提高患者3年生存率.

Effects of perioperative intraperitoneal chemotherapy with 5-fluorouracil sustained release agent on advanced gastric cancer

Objective To investigate the effects of perioperative intraperitoneal chemotherapy with 5-fluorouracil (5-FU) sustained release agent on the local recurrence and survival rates of patients with advanced gastric cancer. Methods The clinical data of 100 patients with advanced gastric cancer who had been admitted to our hospital from January 2002 to December 2004 were retrospectively analyzed. All patients were divided into treatment group and control group. Only patients in the treatment group were implanted with 5-FU sustained release agent (800 mg) in abdominal cavity after D2 gastrectomy. All patients accepted chemotherapy according to the FOLFOX regimen. Results The 3-year survival rate and 3-year disease free survival rate were 45% and 28% for treatment group, which were significantly higher than 32% and 16% for control group. Conclusions Intraperi-toneal implantation of 5-FU sustained release agent during operation can decrease local recurrence rate and improve the 3-year survival rate of patients with advanced gastric cancer after radical gastrectomy.